Abstract:Tuberculosis (TB) is one of the world's most pernicious diseases mainly due to immune evasion strategies displayed by its causative agent Mycobacterium tuberculosis (Mtb). Blood monocytes (Mos) represent an important source of DCs during chronic infections; consequently, the alteration of their differentiation constitutes an escape mechanism leading to mycobacterial persistence. We evaluated whether the CD16 + /CD16 − Mo ratio could be associated with the impaired Mo differentiation into DCs found in TB patien… Show more
“…For example, unlike our findings, some of previous studies have demonstrated that CD14 + CD16 + monocytes differentiate into CD1a -DCs exhibiting low immunostimulatory potencies, compared to CD1a + DCs differentiated from CD14 + CD16 -monocytes [18,19]. In addition, monocytes consisting of mostly CD14 + CD16 -cells could differentiate into CD1a -DCs upon exposure to inflammatory mediators such as microbial molecular patterns [34] and phospholipid metabolites including PGE2 [29,32].…”
contrasting
confidence: 82%
“…Monocytes consist of two populations, CD14 + CD16 -classical monocytes and CD14 + CD16 + non-classical monocytes [17], which differentiate into distinct DC subsets [18,19]. The proportion of CD14 + CD16 + monocytes is significantly increased in the blood of patients with systemic inflammatory diseases such as bacterial sepsis [20].…”
Human umbilical cord blood (UCB) is rich in diverse hematopoietic stem cells that are competent to differentiate into various cell types with immunological compatibility at transplantation. Thus, UCB is a potential source for the preparation of dendritic cells (DCs) to be used for cell therapy against inflammatory disorders or cancers. However, the immunological properties of UCB-derived DCs are not fully characterized. In this study, we investigated the phenotypes and functions of UCB monocyte-derived DCs (UCB-DCs) in comparison with those of adult peripheral blood (APB) monocyte-derived DCs (APB-DCs). UCB-DCs contained less CD1a(+) DCs, which is known as immunostimulatory DCs, than APB-DCs. UCB-DCs exhibited lower expression of CD80, MHC proteins, and DC-SIGN, but higher endocytic activity, than APB-DCs. Lipopolysaccharide stimulation of UCB-DCs minimally augmented the expression of maturation markers and production of interleukin (IL)-12 and tumor necrosis factor (TNF)-α, but potently expressed IL-10. When UCB-DCs were cocultured with CD14(+) cell-depleted allogeneic peripheral blood mononuclear cells, they weakly induced the proliferation, surface expression of activation markers, and interferon (IFN)-γ production of T lymphocytes compared with APB-DCs. UCB possessed higher levels of prostaglandin E2 (PGE2) than APB, which might be responsible for tolerogenic phenotypes and functions of UCB-DCs. Indeed, APB-DCs prepared in the presence of PGE2 exhibited CD1a(-)CD14(+) phenotypes with tolerogenic properties, including weak maturation, impaired IL-12 production, and negligible T lymphocyte activation as UCB-DCs did. Taken together, we suggest that UCB-DCs have tolerogenic properties, which might be due to PGE2 highly sustained in UCB.
“…For example, unlike our findings, some of previous studies have demonstrated that CD14 + CD16 + monocytes differentiate into CD1a -DCs exhibiting low immunostimulatory potencies, compared to CD1a + DCs differentiated from CD14 + CD16 -monocytes [18,19]. In addition, monocytes consisting of mostly CD14 + CD16 -cells could differentiate into CD1a -DCs upon exposure to inflammatory mediators such as microbial molecular patterns [34] and phospholipid metabolites including PGE2 [29,32].…”
contrasting
confidence: 82%
“…Monocytes consist of two populations, CD14 + CD16 -classical monocytes and CD14 + CD16 + non-classical monocytes [17], which differentiate into distinct DC subsets [18,19]. The proportion of CD14 + CD16 + monocytes is significantly increased in the blood of patients with systemic inflammatory diseases such as bacterial sepsis [20].…”
Human umbilical cord blood (UCB) is rich in diverse hematopoietic stem cells that are competent to differentiate into various cell types with immunological compatibility at transplantation. Thus, UCB is a potential source for the preparation of dendritic cells (DCs) to be used for cell therapy against inflammatory disorders or cancers. However, the immunological properties of UCB-derived DCs are not fully characterized. In this study, we investigated the phenotypes and functions of UCB monocyte-derived DCs (UCB-DCs) in comparison with those of adult peripheral blood (APB) monocyte-derived DCs (APB-DCs). UCB-DCs contained less CD1a(+) DCs, which is known as immunostimulatory DCs, than APB-DCs. UCB-DCs exhibited lower expression of CD80, MHC proteins, and DC-SIGN, but higher endocytic activity, than APB-DCs. Lipopolysaccharide stimulation of UCB-DCs minimally augmented the expression of maturation markers and production of interleukin (IL)-12 and tumor necrosis factor (TNF)-α, but potently expressed IL-10. When UCB-DCs were cocultured with CD14(+) cell-depleted allogeneic peripheral blood mononuclear cells, they weakly induced the proliferation, surface expression of activation markers, and interferon (IFN)-γ production of T lymphocytes compared with APB-DCs. UCB possessed higher levels of prostaglandin E2 (PGE2) than APB, which might be responsible for tolerogenic phenotypes and functions of UCB-DCs. Indeed, APB-DCs prepared in the presence of PGE2 exhibited CD1a(-)CD14(+) phenotypes with tolerogenic properties, including weak maturation, impaired IL-12 production, and negligible T lymphocyte activation as UCB-DCs did. Taken together, we suggest that UCB-DCs have tolerogenic properties, which might be due to PGE2 highly sustained in UCB.
“…Together, the modulation of these factors may be responsible for a bystander effect that allows M. tuberculosis to subvert the differentiation of monocytes into dendritic cells that are deficient in priming naïve T cells and, instead, contribute to pathogenic dissemination (Mariotti et al 2002;Skold and Behar 2008;Rajashree et al 2009). This premise is in line with the imbalance in the relative proportions of blood-circulating monocytes observed in tuberculosis patients, in which the abundance of the CD14 þ CD16 þ subset is accentuated and shown to have a defective differentiation program toward functional dendritic cells (Vanham et al 1996;Balboa et al 2013). In the case of IL-10, it was shown to be part of the bystander effect induced by M. tuberculosis to inhibit the differentiation of human monocytes into CD1c þ DCs, suggesting it plays an important role in the recruitment of dendritic cell precursors that may be incapable to activate efficiently the adaptive immune response (Remoli et al 2011).…”
Section: Dendritic Cell Differentiation and Activation: Manipulation supporting
Over the past 20 years, there has been an emerging appreciation about the role of the mononuclear phagocyte system (MPS) to control and eradicate pathogens. Likewise, there have been significant advances in dissecting the mechanisms involved in the microbial subversion of MPS cells, mainly affecting their differentiation and effector functions. Mycobacterium tuberculosis is a chronic bacterial pathogen that represents an enigma to the field because of its remarkable ability to thrive in humans. One reason is that M. tuberculosis renders a defective MPS compartment, which is perhaps the most ingenious strategy for survival in the host given the prominence of these cells to modulate microenvironments, their function as sentinels and orchestrators of the immune response, and their pathogenic role as reservoirs for microbial persistence. In this article, the principal strategies used by M. tuberculosis to subvert the MPS compartment are presented along with emerging concepts.
“…This unbalance in the monocyte population is also associated with a higher cell-surface expression for CD14, CD11b, toll-like receptor-2 (TLR2), TLR5, chemokine C-C motif receptor-1 (CCR1), CCR2 and CCR5, as compared with that of healthy individuals [18]. Functional characterization in vitro shows that monocytes isolated from TB patients are refractory to efficient dendritic cell (DC) differentiation and deficient in the activation of T lymphocytes, as compared with monocytes from healthy donors [19,20]. The cause and consequence of this unbalance are still relatively unknown.…”
The human CD14 + monocyte compartment is composed by two subsets based on CD16 expression. We previously reported that this compartment is perturbed in tuberculosis (TB) patients, as reflected by the expansion of CD16 + monocytes along with disease severity. Whether this unbalance is beneficial or detrimental to host defense remains to be elucidated. Here in the context of active TB, we demonstrate that human monocytes are predisposed to differentiate towards an anti-inflammatory (M2-like) macrophage activation program characterized by the CD16 + CD163 + MerTK + pSTAT3 + phenotype and functional properties such as enhanced protease-dependent motility, pathogen permissivity and immunomodulation. This process is dependent on STAT3 activation, and loss-of-function experiments point towards a detrimental role in host defense against TB. Importantly, we provide a critical correlation between the abundance of the CD16 + CD163 + MerTK + pSTAT3 + cells and the progression of the disease either at the local level in a non-human primate tuberculous granuloma context, or at the systemic level through the detection of the soluble form of CD163 in human sera. Collectively, this study argues for the pathogenic role of the CD16 + C-D163 + MerTK + pSTAT3 + monocyte-to-macrophage differentiation program and its potential as a target for TB therapy, and promotes the detection of circulating CD163 as a potential biomarker for disease progression and monitoring of treatment efficacy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.